title: [Effect of chronic administration of epaden and acetylsalicylic acid on the antithrombotic potential of blood vessel walls in rabbits].
abstract: The effect of a new domestic polyunsaturated fatty acid (PUFA) concentrate called epaden on the blood coagulation system was studied in comparison with acetylsalicylic acid (ASA). The antithrombotic potential of the blood vessel wall was determined by release of the inhibitors of thrombocyte aggregation, fibrinolysis activators, and anticoagulants in rabbits under immobilization induced stress conditions. In the control group, the immobilization stress resulted in a decrease of the collagen-induced platelet aggregation, a drop in the fibrinogen level, and an increase in the tissue-type plasminogen activator (t-PA) activity. The administration of ASA and epaden reduced a drop in the fibrinogen level caused by the immobilization stress. Animals receiving epaden showed a decrease in the ADP-induced platelet aggregation and an increase in the t-PA activity in comparison with the levels before modeling stressed conditions. No such effect was observed in the group treated with ASA. It is suggested that the additional antithrombotic effect of epaden observed under the immobilization stress conditions is related to a protective action of this substance on the vessel wall.
authors.affiliation: Laboratory of Hemostasis Pathology and Pharmacology, Scientific Hematology Center, Russian Academy of Medical Sciences, Novo-Zykovskii proezd 4a, Moscow, 125167 Russia.
authors.forename: G N
authors.initials: GN
authors.lastname: Petrukhina
authors.forename: M N
authors.initials: MN
authors.lastname: Remov
authors.forename: V A
authors.initials: VA
authors.lastname: Makarov
authors.forename: V G
authors.initials: VG
authors.lastname: Gandel'
mesh_terms: D000818:Animals; D001241:Aspirin / Q000494:pharmacology; D001808:Blood Vessels / Q000187:drug effects* / Q000378:metabolism; D016861:Cyclooxygenase Inhibitors / Q000494:pharmacology; D015525:Fatty Acids, Omega-3 / Q000494:pharmacology*; D005340:Fibrinogen / Q000032:analysis; D005342:Fibrinolysis / Q000187:drug effects; D007103:Immobilization; D010974:Platelet Aggregation / Q000187:drug effects; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology*; D010976:Platelet Count; D011517:Prothrombin Time; D011817:Rabbits; D013315:Stress, Psychological / Q000097:blood; D010959:Tissue Plasminogen Activator / Q000097:blood
chemical_list: D016861:Cyclooxygenase Inhibitors; D015525:Fatty Acids, Omega-3; D010975:Platelet Aggregation Inhibitors; C408245:epaden; D005340:Fibrinogen; D010959:Tissue Plasminogen Activator; D001241:Aspirin